July 2014

Conference to Translate Targeted Therapy Data for Community Practice

September 08, 2014

Clinical Articles

In 2001, the FDA approved Gleevec (imatinib mesylate), a therapy for CML that was quickly labeled a magic bullet, and shortly thereafter, the International Congress on Targeted Therapies in Cancer® was assembled to discuss what these types of therapies would mean for the cancer treatment of the future.